Skip to main content
. 2021 Oct 15;12:6023. doi: 10.1038/s41467-021-26299-4

Fig. 5. Pathway-based super signature for on-treatment samples.

Fig. 5

a–c The heatmap of ssGSEA values of on-treatment responders (R) and nonresponders (NR)in the Gide et al. cohort (a), Lee et al. cohort (b), and MGH cohort (c). Nonresponders are presented on the left side, and responders are presented on the right side. FDR-corrected two-sided Welch t-test was conducted to compare ssGSEA values between R and NR samples, only FDR < 0.05 showed here. d–f The boxplot of on-treatment samples’ PASS-ON signature scores in the Gide et al. cohort (d), Lee et al. cohort (e), and MGH cohort (f). The on-treatment samples were separated into responders (R) and nonresponders (NR) with number of samples showed in each cohorts. The P-values were computed via a one-sided rank-sum test. Boxplot center lines indicate medians, box edges represent the interquartile range, and the outliers are plotted individually using the ‘*’ symbol. g ROC and AUC PASS-ON on the on-treatment samples from Gide et al., Lee et al., and MGH cohorts. h ROC and AUC on the all on-treatment test samples which combined with Gide et al., Lee et al., and MGH cohorts. i–k The Kaplan–Meier analysis of progression-free survival (PFS) of on-treatment samples in the combined test on-treatment samples (i), Gide et al. cohorts (j), and MGH cohorts (k). The two-sided log-rank test compared high and low subgroups based on the mean of on-treatment samples’ odd ratio as cutoff. Hazard ratio (HR) was calculated and shown with confidence interval (CI). Source data are provided as a Source Data file.